Improvement of the Nutritional Status Regarding Nicotinamide (Vitamin B3) and the Disease Course of COVID-19
Launched by UNIVERSITY HOSPITAL SCHLESWIG-HOLSTEIN · Feb 9, 2021
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • The patient is of age (at least 18 years).
- • SARS-CoV-2 infection confirmed by laboratory findings; the positive test must not date back more than 7 days.
- • Relevant infection symptoms, e.g. in the respiratory or gastrointestinal tract.
- • The patient has been able to give written consent via a website before any trial procedure is performed and can comply with the trial-dependent prerequisites and requirements.
- Exclusion Criteria:
- • Current participation in another trial.
- • Pregnancy or breastfeeding.
- • Vaccination against SARS-CoV-2.
About University Hospital Schleswig Holstein
University Hospital Schleswig-Holstein (UKSH) is a leading academic medical center in Germany, renowned for its commitment to advancing healthcare through innovative research and clinical trials. As a prominent institution, UKSH integrates cutting-edge medical research with comprehensive patient care, fostering an environment that promotes the development of novel therapeutic strategies. With a multidisciplinary approach and a strong emphasis on collaboration, UKSH is dedicated to enhancing clinical outcomes and contributing to the global medical community through rigorous scientific inquiry and the translation of research findings into practice.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Kiel, Schleswig Holstein, Germany
Patients applied
Trial Officials
Stefan Schreiber, MD
Principal Investigator
University Hospital Schleswig-Holstein
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials